^
    Back
    Association details:
    Biomarker:CD22 underexpression + BCL2 overexpression
    Cancer:Acute Lymphocytic Leukemia
    Drug:Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    CD22low/Bcl-2high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

    Published date:
    11/04/2021
    Excerpt:
    Inotuzumab ozogamicin (InO)...In order to identify better predictors of response to InO, we analyzed 68 samples from 28 patients with multiply R/R ALL enrolled in Children’s Oncology Group trial AALL1621 (NCT02981628)...CD22high expression predicting good response to InO versus CD22low/Bcl-2high expression predicting poor response.
    DOI:
    10.1182/blood-2021-149037
    Trial ID:
    AALL1621